A pilot open-label study of aldose reductase inhibition with AT-001 (caficrestat) in patients hospitalized for COVID-19 infection: Results from a registry-based matched-control analysis

Mostrar otras versiones (1)

BACKGROUND AND AIMS: Cardiometabolic disease may confer increased risk of adverse outcomes in COVID-19 patients by activation of the aldose reductase pathway. We hypothesized that aldose reductase inhibition with AT-001 might reduce viral inflammation and risk of adverse outcomes in diabetic patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaztanaga, Juan, Ramasamy, Ravichandran, Schmidt, Ann Marie, Fishman, Glenn, Schendelman, Shoshana, Thangavelu, Karthinathan, Perfetti, Riccardo, Katz, Stuart D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd on behalf of Diabetes India. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556062/
https://www.ncbi.nlm.nih.gov/pubmed/34752935
http://dx.doi.org/10.1016/j.dsx.2021.102328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556062/
https://www.ncbi.nlm.nih.gov/pubmed/34752935
http://dx.doi.org/10.1016/j.dsx.2021.102328

Ejemplares similares